Lantern Pharma Inc. received clearance from the European Medicines Agency (EMA) to launch a Phase 1b/2 clinical trial for its lead candidate, LP-184. The study targets patients with advanced, recurrent bladder cancer.
Rigshospitalet in Copenhagen, Denmark, will conduct the investigator-initiated trial. The study utilizes a dual-biomarker strategy to identify patients most likely to respond to treatment.
This precision oncology approach combines PTGR1 overexpression with tumor-specific DNA damage repair deficiencies. The trial expects to enroll approximately 39 patients who have exhausted standard therapies.
LP-184 currently holds U.S. FDA Fast Track and Orphan Drug designations for other cancer indications.